May Daher
@may_daher
Followers
1K
Following
3K
Media
4
Statuses
491
Physician scientist at MD Anderson Cancer Center with focus on cellular therapy, gene editing and immunometabolism to treat cancer patients. Tweets are my own.
Houston, TX
Joined December 2015
Does your gene therapy turn on in the wrong cells?! ⚠️ We have the solution Our tech is funded by ARPA-H to create potent and safe in vivo cell therapies in collab with John Hopkins @NCBIB_JHTIE led by @JGreenGroup @SchneckJonathan MDAnderson led by @lab_rezvani @may_daher
1
1
7
Beautiful work detailing a key cause of immune system dysfunction - a critical factor to understand as we lean into a future of harnessing the immune system for cancer control. @OSUCCC_James @Zihai @OhioStatePIIO
Our new @Nature study reveals a proteotoxic shock as a key mechanism of T-cell exhaustion. TexPSR (proteotoxic stress response in T-cell exhaustion) is driven by increased protein synthesis + buildup of misfolded proteins, leading to T-cell dysfunction. 👉 https://t.co/154ORc2MnD
3
3
27
Proud of my PhD student @MalihaMunir2025 for receiving the Kopchick Fellowship for her project focusing on enhancing #NK cell #metabolism and cytotoxicity in the solid tumor #TME. Looking forward to her continued success!@MDAndersonNews
gsbs.uth.edu
3
3
28
It was a pleasure to share some of our work highlighting novel NK cell engineering strategies and progress in clinical trials at #SOHO2025. Great to reconnect with hematology colleagues from around the country! Thanks to @drsairahahmed and @RShouval for moderating a great
3
4
39
Beautiful work that can be applied to enhance the field of immunometabolism! Congratulations @thalexandrov and team! #metabolomics #immunometabolism
Our team is excited and honored to see our new method, HT SpaceM, for high-throughput single-cell metabolomics published in Cell! https://t.co/OEgNiEHgib 👇
2
1
16
Results from a study open new avenues for discovering approaches to enhance the antitumor activity of CAR NK cell therapies against multiple cancer types via a comprehensive CRISPR discovery platform optimized for primary human NK cells. Read more:
mdanderson.org
Natural killer (NK) cells became markedly better at killing cancer cells after scientists removed key gene targets identified through a new genome-wide CRISPR screening tool, according to new...
6
21
62
Congratulations @ABiederstadt_MD @rftbsr9 @lab_Rezvani on this tour de force! Very important findings for the #NK cell therapy field. #NK #CRISPR #CRISPRscreen
Delighted to share our Cancer Cell paper published today, co-authored by Dr. Alexander Biederstädt @ABiederstadt_MD and Dr. Rafet Basar @rftbsr9 reporting the first genome-wide CRISPR screen in primary cord blood NK and CAR NK cells. We identify key genetic checkpoints including
1
2
18
It was a pleasure writing this preview with @lab_rezvani in @CellCellPress highlighting this first-in-human trial showing the promise of iPSC-derived CAR-NK cells for autoimmune disease! The future is bright! #CARNK #Autoimmunity #Beyondcancer @MDAndersonNews
@CellCellPress preview by @lab_rezvani @may_daher iPSC-derived CAR-NK cells: Off-the-shelf cellular therapy for systemic sclerosis https://t.co/QNQZ69KSb4 on https://t.co/cjtjbqncuP
9
23
81
Congratulations @paulbeavis4 and team on this beautiful story. Very promising approach using armoured CAR-T cells designed to enhance efficacy while decreasing toxicity, with high translational value for solid tumors. Looking forward to seeing responses in patients with solid
Delighted to share our new approach to enhance CAR T cell function in solid tumours published today @Nature. In this work we identify a new strategy to generate armoured CAR T cells.
2
3
9
Congratulations @Dr_Nick_Bikes, Jai Rautela and team on this very elegant work! CRISPR screens will definitely advance the field of NK and CAR-NK cell therapy. Looking forward to the clinical translation of the uncovered hits! #NK #CARNK #CRISPRscreen
Excited to share our Cancer Cell @CellPressNews article on the discovery of the IL-15 Receptor "Regulome". A technical tour-de-force from the Immunology, computational biology & functional genomics teams @oNKo_innate @MonashBDI
1
4
16
CISH KO TILs showing promise in a phase I clinical trial in patients with metastatic colorectal cancer! Congratulations fo @KlebanoffLab and the team! Excited to see the potential of CISH KO immune cells in the clinic! #CISH #CRISPR #TILs
👉Today in @TheLancetOncol: phase I trial of #CISH KO #neoantigen-selected #TIL in GI cancers. Proud to have worked in collaboration with @cancerassassin1, the Webber/Moriarity labs @UMNCancer, and #IntimaBioscience from pre-clinical->IND->first-in-human.
0
1
15
Congratulations @ABiederstadt_MD ! Hate to have missed it. I am sure it was amazing! looking forward to your paper! #CRISPRscreen #CAR #NK @MDAndersonNews @lab_rezvani
Congratulations to @ABiederstadt_MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells @MDAndersonNews
1
1
15
This morning at #AACR25, our Dr. Katy Rezvani shared an overview of her team’s wide-ranging CAR NK cell platform targeting hematological malignancies and solid tumors, leading to 12 ongoing clinical trials. @lab_rezvani
@AACR #EndCancer
5
28
114
Congratulations to Courtney D. DiNardo, MD, MSCE, and colleagues, recipients of the 2025 Blood Cancer Discovery Award for Outstanding Journal Article. Learn more: https://t.co/riwOhFKWc0
#AACR25 @MDAndersonNews @AACR
0
3
14
The MD Anderson community will dearly miss you and @nyulangone is lucky to have you. Enjoy this next chapter of your career Dr.Maitra! @aiims1742 @MDAndersonNews
🤠 👉🏽 🗽 news: I will be joining @nyulangone on September 1, 2025 as Director of the GI Cancer Center & Associate Director of Translational Research at @Perlmutter_CC. I am excited to start the next chapter of the Maitra Lab in NYC & build a strong GI cancer research program.
0
0
6
Congratulations Irene! It was an amazing collaboration! 🎉🎊 thank you for all your hard work! #NK #CCUS #MDS @MDAndersonNews @CollaSimona
Just out!! Our work on NK cells dysfunction in patients with clonal cytopenias frequently preceding MDS is finally published in @NatureComms! This was a collab between the #collalab and @may_daher @MDAndersonNews 👉
1
1
6
Thank you for the shoutout @lab_rezvani ! The potential of NK cell therapy for MDS/AML is huge! @MDAndersonNews #MDS #NK
Brilliant work! congratulations, @may_daher and @CollaSimona and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing
0
2
12
Interestingly, we also found that BATF plays a central role in this NK cell dysfunction in CCUS/earlyMDS validating our recently published data in the setting of AML! https://t.co/5jwm13k7nt
pubmed.ncbi.nlm.nih.gov
Myelodysplastic syndrome and acute myeloid leukemia (AML) belong to a continuous disease spectrum of myeloid malignancies with poor prognosis in the relapsed/refractory setting necessitating novel...
0
0
14
Very excited to share our latest research article published with @SpringerNature in @NatureComms. We show that in early #MDS, NK cells share mutations with the malignant clones, becoming dysfunctional and failing to eliminate aberrant stem cells. This leads to immune evasion and
12
19
94
This will be an amazing symposium for those interested in myeloid malignancies. Checkout the exciting program organized by @CollaSimona ! I will be presenting some of our work on NK cell epigenetic scarring in MDS and AML. @MDAndersonNews #MDS #AML #NK
Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. @CollaSimona at @MDAndersonNews in May 2025! The speaker line up is phenomenal & the science is cutting edge. Register 👇🏼 join us & RT pls https://t.co/GQ94GCpP6C
#MDSsm
1
7
23